

3D Bioprinting Market Report by Component (3D Bioprinters, Scaffolds, Biomaterials), Application (Research, Clinical), End User (Hospitals, Research Organization and Academic Institutes, Biopharmaceuticals Companies), and Region 2026-2034

Market Report | 2026-02-01 | 142 pages | IMARC Group

AVAILABLE LICENSES:

- Electronic (PDF) Single User \$3999.00
- Five User Licence \$4999.00
- Enterprisewide License \$5999.00

Report description:

The global 3D bioprinting market size reached USD 1,575.3 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 5,040.0 Million by 2034, exhibiting a growth rate (CAGR) of 13.38% during 2026-2034. The growing geriatric population, increasing focus on research and development (R&D) activities, and less disrupted market represent some of the key factors driving the market growth.

3D Bioprinting Market Analysis:

- **Major Market Drivers:** The increasing utilization of 3D bioprinting in personalized medicine is primarily driving the growth of the market. 3D bioprinting can create patient-specific tissues and organs, enabling personalized treatment plans and reducing the risk of transplant rejection.
- **Key Market Trends:** The escalating utilization of bioprinting to manufacture complex biomedical devices and implants with precise geometries and biological functionalities is one of the significant trends driving the growth of the market. Furthermore, rapid advancements in 3D bioprinting technology, including improved biomaterials and printing techniques, are also contributing to the market expansion.
- **Competitive Landscape:** Some of the leading players operating in the global market include 3D Systems Inc., Aspect Biosystems Ltd., Cellink, Cyfuse Biomedical K.K., EnvisionTEC GmbH (Desktop Metal Inc.), GeSiM - Gesellschaft für Silizium-Mikrosysteme mbH, Materialise, Organovo Holdings Inc., Poietis, RegenHU, and Stratasys Ltd., among others.
- **Geographical Landscape:** According to the report, North America (the United States and Canada) was the largest market for 3D bioprinting. Some of the factors driving the North American 3D bioprinting market include the growing prevalence of various

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

chronic diseases, the wide presence of key players, and increasing private and government investment.

-□Challenges and Opportunities: The global 3D bioprinting market faces challenges such as high costs, technical complexities, and regulatory hurdles. However, it presents opportunities to advance personalized medicine, improve drug testing accuracy, and address organ transplant shortages through innovative tissue engineering solutions.

3D Bioprinting Market Trends:

Increasing Drug Testing and Development

3D bioprinters are highly important for drug testing and clinical trial applications. They are expected to drastically reduce the need for animal trials, thus being ethically beneficial and cost-effective. With the advent of 3D bioprinting, drug developers can easily identify complications associated with human clinical trials by testing new drugs on human-like 3D-printed tissues, thereby reducing losses from late-stage failures. Additionally, the increasing investment in research and development by the companies is further escalating the demand for innovative technologies like 3D bioprinting. For instance, according to the data published by the Congressional Budget Office, in 2021, it has been observed that pharmaceutical industries spent nearly US\$ 200 Billion on research and development in 2020 globally compared to US\$ 83 Million in 2019. Similarly, Danaher Corporation invested US\$ 1,742 Million in its research and development in 2021, as compared to US\$ 1,348 Million in 2020. In addition, Bio-Rad Laboratories Inc. invested US\$ 879.6 Million in 2021 as compared to US\$ 800.3 Million in 2020. Such significant investments in drug trials and drug development are anticipated to propel the 3D bioprinting market size in the coming years.

Technological Advancements

Ongoing technological advancements in 3D bioprinting are further offering lucrative growth opportunities to the overall market. Additionally, various leading market players are collaborating and forming partnerships to develop more advanced and efficient 3D bioprinting technologies. For instance, in June 2024, advanced tissue mimetic technologies company Ronawk partnered with B9Creations to develop and mass-produce 3D bioprinted hydrogels leveraging Ronawk's Bio-Blocks. Unlike traditional methods that force cells into artificial environments, Ronawk's Bio-Blocks recreate conditions that allow cells to form tissues naturally. This results in tissue that closely resembles the native architecture and function of human and animal tissues. Similarly, in September 2022, the Indian Institute of Science (IISc) announced its collaboration with CELLINK, a Sweden-based bioprinting solutions company, to provide two to three bioprinters to the Centre of Excellence (CoE), each of which uses a different printing technology at its own cost. Additionally, in December 2022, CELLINK and IISc jointly established Bengaluru's pioneering 3D Bioprinting Centre of Excellence in India. Such innovations, collaborations, and expansion in 3D bioprinting are projected to positively impact the 3D bioprinting market outlook over the forecasted period.

Growing Product Application in Cancer Research

3D bioprinting is widely used in the creation of realistic tumor models that closely mimic the complexity and microenvironment of actual human tumors. These bioprinted models enable researchers to study cancer progression, metastasis, and tumor-stroma interactions in a controlled setting. Moreover, the escalating cases of cancer across the globe are further offering lucrative growth opportunities to the overall market. For instance, the International Agency for Research on Cancer (IARC) estimated that, in the year 2020, there were about 19.29 million cancer cases. These cases are projected to increase to 24.58 million cases by 2030. Additionally, according to GLOBOCAN, in 2020, there were approximately 2,281,658 new cancer cases diagnosed and 612,390 deaths due to cancer alone in the United States. In addition to this, lung cancer and breast cancer are two of the most common cancers found among individuals. The Canadian Cancer Society (CCS) stated that in 2020, nearly 29,800 Canadians were diagnosed with lung cancer, which accounted for 13% of all new cancer cases. About 21,200 Canadians were expected to die from lung cancer, which represented 25% of all cancer deaths in 2020. Such a substantial growth in cancer cases is augmenting the demand for 3D bioprinting technologies that help identify effective treatments, understand drug resistance mechanisms, and personalize cancer therapies.

Global 3D Bioprinting Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global 3D bioprinting market report, along with

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

forecasts at the global, regional, and country levels from 2026-2034. Our report has categorized the market based on component, application, and end user.

Component Insights:

- 3D Bioprinters
 - o□Syringe/Extrusion Bioprinting
 - o□Inkjet Bioprinting
 - o□Magnetic Levitation Bioprinting
 - o□Laser-assisted Bioprinting
 - o□Others
- Scaffolds
- Biomaterials
 - o□Living Cells
 - o□Hydrogels
 - o□Extracellular Matrices
 - o□Others

3D bioprinters (syringe/extrusion bioprinting, inkjet bioprinting, magnetic levitation bioprinting, laser-assisted bioprinting, and others) represented the largest segment

The 3D bioprinting market research report has provided a detailed breakup and analysis of the 3D bioprinting market based on the component. This includes 3D bioprinters (syringe/extrusion bioprinting, inkjet bioprinting, magnetic levitation bioprinting, laser-assisted bioprinting, and others), scaffolds, and biomaterials (living cells, hydrogels, extracellular matrices, and others). According to the report, 3D bioprinters (syringe or extrusion bioprinting, inkjet bioprinting, magnetic levitation bioprinting, laser-assisted bioprinting, and others) represented the largest segment.

The bolstering demand for 3D bioprinters can be attributed to the increasing utilization of syringe or extrusion-based bioprinting technology in printing various biological compounds or devices. They are widely used in fabricating tissue scaffolds for regenerative medicine, developing organ models for transplant research, and creating realistic tissue models for drug testing and cancer research. Moreover, 3D bioprinters have the ability to produce complex, customized biological structures, improve the accuracy of drug testing, and reduce the need for animal testing. As a result, they are widely used in the fields of tissue engineering, personalized medicine, pharmaceutical development, and medical research.

Application Insights:

- Research
 - o□Drug Research
 - o□Regenerative Medicine
 - o□3D Cell Culture
- Clinical
 - o□Skin
 - o□Bone and Cartilage
 - o□Blood Vessels
 - o□Others

Research (drug research, regenerative medicine, and 3D cell culture) accounted for the largest market share

A detailed breakup and analysis of the 3D bioprinting market based on the application has also been provided in the report. This includes research (drug research, regenerative medicine, and 3D cell culture) and clinical (skin, bone and cartilage, blood vessels, and others). According to the report, research (drug research, regenerative medicine, and 3D cell culture) accounted for the largest market share.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The growth of this segment can be attributed to the widespread utilization of 3D printing technology among researchers to study the effects of different diseases and their progression and possible treatments. Moreover, it reduces the need to use lab animals for medical tests and dangerous trials on humans. Additionally, the 3D bioprinting market forecast by IMARC indicates that the increasing drug development and drug trial activities are bolstering the application of 3D bioprinting in research. For instance, with the COVID-19 pandemic behind, the US Food and Drug Administration (FDA) approved 55 new drugs in 2023, a figure consistent with the number authorized in the last five years (53 per year on average). Thus, 2023 marks the second-best yearly FDA harvest after 2018 (59 approvals) in all the series. Such a significant growth in drug trials and approval is creating a positive outlook for the overall market.

End User Insights:

- Hospitals
- Research Organization and Academic Institutes
- Biopharmaceuticals Companies

Biopharmaceuticals companies accounted for the largest market share

A detailed breakup and analysis of the 3D bioprinting market based on the end user has also been provided in the report. This includes hospitals, research organization and academic institutes, and biopharmaceuticals companies. According to the report, biopharmaceuticals companies accounted for the largest market share.

The 3D bioprinting market statistics by IMARC indicate that the increasing number of target therapies is primarily driving the growth of this segment. In addition to this, the rising collaborations and mergers and acquisition activities among biopharmaceutical companies to develop 3D bioprinting are positively influencing the market. For instance, in June 2022, REGEMAT 3D, a company at the forefront of personalized bio fabrication solutions, announced a partnership with Humabiologics, a company providing human-derived biomaterials for regenerative medicine, in response to the growing demand and to serve a broader life sciences customer base of the industry partners and academic institutions in the European bioprinting and drug testing market.

Regional Insights:

- North America
 - o□United States
 - o□Canada
- Asia-Pacific
 - o□China
 - o□Japan
 - o□India
 - o□South Korea
 - o□Australia
 - o□Indonesia
 - o□Others
- Europe
 - o□Germany
 - o□France
 - o□United Kingdom
 - o□Italy
 - o□Spain
 - o□Russia
 - o□Others
- Latin America
 - o□Brazil

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- o Mexico
- o Others
- Middle East and Africa

North America (the United States and Canada) was the largest market for 3D bioprinting

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

According to the report, North America (the United States and Canada) was the largest market for 3D bioprinting.

Some of the factors driving the North American 3D bioprinting market included the growing prevalence of various chronic diseases, the presence of key players, and increasing private and government investments. Additionally, new product launches by the key market players in the region, along with the easy allocation of funds to conduct R&D activities, are further creating a positive outlook for the overall market. For instance, in 2022, scientists from Florida Atlantic University and the University of Virginia created a robotic model of the human spine to assist surgeons in anticipating the outcomes of interventions before surgery. Thus, the increasing demand for 3D bioprinting for healthcare physicians is expected to boost the market over the forecast period. Additionally, the rising investments by the regional government authorities in the healthcare sector are projected to propel the 3D bioprinting market share in the coming years.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global 3D bioprinting market. Some of the companies covered in the report include:

- 3D Systems Inc.
- Aspect Biosystems Ltd.
- Cellink
- Cyfuse Biomedical K.K.
- EnvisionTEC GmbH (Desktop Metal Inc.)
- GeSiM - Gesellschaft für Silizium-Mikrosysteme mbH
- Materialise
- Organovo Holdings Inc.
- Poietis
- RegenHU
- Stratasys Ltd.

Key Questions Answered in This Report

1. What was the size of the global 3D bioprinting market in 2025?
2. What is the expected growth rate of the global 3D bioprinting market during 2026-2034?
3. What are the key factors driving the global 3D bioprinting market?
4. What has been the impact of COVID-19 on the global 3D bioprinting market?
5. What is the breakup of the global 3D bioprinting market based on the component?
6. What is the breakup of the global 3D bioprinting market based on the application?
7. What is the breakup of the global 3D bioprinting market based on the end user?
8. What are the key regions in the global 3D bioprinting market?
9. Who are the key players/companies in the global 3D bioprinting market?

Table of Contents:

- 1 Preface
- 2 Scope and Methodology

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
 - 4.1 Overview
 - 4.2 Key Industry Trends
- 5 Global 3D Bioprinting Market
 - 5.1 Market Overview
 - 5.2 Market Performance
 - 5.3 Impact of COVID-19
 - 5.4 Market Forecast
- 6 Market Breakup by Component
 - 6.1 3D Bioprinters
 - 6.1.1 Market Trends
 - 6.1.2 Key Segments
 - 6.1.2.1 Syringe/Extrusion Bioprinting
 - 6.1.2.2 Inkjet Bioprinting
 - 6.1.2.3 Magnetic Levitation Bioprinting
 - 6.1.2.4 Laser-assisted Bioprinting
 - 6.1.2.5 Others
 - 6.1.3 Market Forecast
 - 6.2 Scaffolds
 - 6.2.1 Market Trends
 - 6.2.2 Market Forecast
 - 6.3 Biomaterials
 - 6.3.1 Market Trends
 - 6.3.2 Key Segments
 - 6.3.2.1 Living Cells
 - 6.3.2.2 Hydrogels
 - 6.3.2.3 Extracellular Matrices
 - 6.3.2.4 Others
 - 6.3.3 Market Forecast
- 7 Market Breakup by Application
 - 7.1 Research
 - 7.1.1 Market Trends
 - 7.1.2 Key Segments
 - 7.1.2.1 Drug Research
 - 7.1.2.2 Regenerative Medicine
 - 7.1.2.3 3D Cell Culture
 - 7.1.3 Market Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.2 Clinical
 - 7.2.1 Market Trends
 - 7.2.2 Key Segments
 - 7.2.2.1 Skin
 - 7.2.2.2 Bone and Cartilage
 - 7.2.2.3 Blood Vessels
 - 7.2.2.4 Others
 - 7.2.3 Market Forecast
- 8 Market Breakup by End User
 - 8.1 Hospitals
 - 8.1.1 Market Trends
 - 8.1.2 Market Forecast
 - 8.2 Research Organization and Academic Institutes
 - 8.2.1 Market Trends
 - 8.2.2 Market Forecast
 - 8.3 Biopharmaceuticals Companies
 - 8.3.1 Market Trends
 - 8.3.2 Market Forecast
- 9 Market Breakup by Region
 - 9.1 North America
 - 9.1.1 United States
 - 9.1.1.1 Market Trends
 - 9.1.1.2 Market Forecast
 - 9.1.2 Canada
 - 9.1.2.1 Market Trends
 - 9.1.2.2 Market Forecast
 - 9.2 Asia-Pacific
 - 9.2.1 China
 - 9.2.1.1 Market Trends
 - 9.2.1.2 Market Forecast
 - 9.2.2 Japan
 - 9.2.2.1 Market Trends
 - 9.2.2.2 Market Forecast
 - 9.2.3 India
 - 9.2.3.1 Market Trends
 - 9.2.3.2 Market Forecast
 - 9.2.4 South Korea
 - 9.2.4.1 Market Trends
 - 9.2.4.2 Market Forecast
 - 9.2.5 Australia
 - 9.2.5.1 Market Trends
 - 9.2.5.2 Market Forecast
 - 9.2.6 Indonesia
 - 9.2.6.1 Market Trends
 - 9.2.6.2 Market Forecast
 - 9.2.7 Others
 - 9.2.7.1 Market Trends

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.2.7.2 Market Forecast
- 9.3 Europe
 - 9.3.1 Germany
 - 9.3.1.1 Market Trends
 - 9.3.1.2 Market Forecast
 - 9.3.2 France
 - 9.3.2.1 Market Trends
 - 9.3.2.2 Market Forecast
 - 9.3.3 United Kingdom
 - 9.3.3.1 Market Trends
 - 9.3.3.2 Market Forecast
 - 9.3.4 Italy
 - 9.3.4.1 Market Trends
 - 9.3.4.2 Market Forecast
 - 9.3.5 Spain
 - 9.3.5.1 Market Trends
 - 9.3.5.2 Market Forecast
 - 9.3.6 Russia
 - 9.3.6.1 Market Trends
 - 9.3.6.2 Market Forecast
 - 9.3.7 Others
 - 9.3.7.1 Market Trends
 - 9.3.7.2 Market Forecast
- 9.4 Latin America
 - 9.4.1 Brazil
 - 9.4.1.1 Market Trends
 - 9.4.1.2 Market Forecast
 - 9.4.2 Mexico
 - 9.4.2.1 Market Trends
 - 9.4.2.2 Market Forecast
 - 9.4.3 Others
 - 9.4.3.1 Market Trends
 - 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
 - 9.5.1 Market Trends
 - 9.5.2 Market Breakup by Country
 - 9.5.3 Market Forecast
- 10 SWOT Analysis
 - 10.1 Overview
 - 10.2 Strengths
 - 10.3 Weaknesses
 - 10.4 Opportunities
 - 10.5 Threats
- 11 Value Chain Analysis
- 12 Porters Five Forces Analysis
 - 12.1 Overview
 - 12.2 Bargaining Power of Buyers

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
- 13 Price Analysis
- 14 Competitive Landscape
 - 14.1 Market Structure
 - 14.2 Key Players
 - 14.3 Profiles of Key Players
 - 14.3.1 3D Systems Inc.
 - 14.3.1.1 Company Overview
 - 14.3.1.2 Product Portfolio
 - 14.3.2 Aspect Biosystems Ltd.
 - 14.3.2.1 Company Overview
 - 14.3.2.2 Product Portfolio
 - 14.3.3 Cellink
 - 14.3.3.1 Company Overview
 - 14.3.3.2 Product Portfolio
 - 14.3.3.3 Financials
 - 14.3.4 Cyfuse Biomedical K.K.
 - 14.3.4.1 Company Overview
 - 14.3.4.2 Product Portfolio
 - 14.3.5 EnvisionTEC GmbH (Desktop Metal Inc.)
 - 14.3.5.1 Company Overview
 - 14.3.5.2 Product Portfolio
 - 14.3.6 GeSiM - Gesellschaft für Silizium-Mikrosysteme mbH
 - 14.3.6.1 Company Overview
 - 14.3.6.2 Product Portfolio
 - 14.3.7 Materialise
 - 14.3.7.1 Company Overview
 - 14.3.7.2 Product Portfolio
 - 14.3.7.3 Financials
 - 14.3.8 Organovo Holdings Inc.
 - 14.3.8.1 Company Overview
 - 14.3.8.2 Product Portfolio
 - 14.3.8.3 Financials
 - 14.3.9 Poietis
 - 14.3.9.1 Company Overview
 - 14.3.9.2 Product Portfolio
 - 14.3.10 RegenHU
 - 14.3.10.1 Company Overview
 - 14.3.10.2 Product Portfolio
 - 14.3.11 Stratasys Ltd.
 - 14.3.11.1 Company Overview
 - 14.3.11.2 Product Portfolio
 - 14.3.11.3 Financials

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

3D Bioprinting Market Report by Component (3D Bioprinters, Scaffolds, Biomaterials), Application (Research, Clinical), End User (Hospitals, Research Organization and Academic Institutes, Biopharmaceuticals Companies), and Region 2026-2034

Market Report | 2026-02-01 | 142 pages | IMARC Group

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Electronic (PDF) Single User	\$3999.00
	Five User Licence	\$4999.00
	Enterprisewide License	\$5999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2026-03-02

Signature

A large, empty rectangular box intended for a signature.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com